摘要
目的观察前列腺素E1(PGE1)联合熊去氧胆酸治疗肝硬化残留黄疸的疗效及安全性。方法将82例早期肝硬化伴残留黄疸的患者随机分为两组,治疗组46例,对照组36例;对照组以常规方法治疗,治疗组在常规治疗方法的基础上加用PGE1联合熊去氧胆酸,疗程30天,分别测定两组治疗前后的总胆红素(TB il)、直接胆红素(DB il),间接胆红素(IB il)、肝动脉阻力指数(R I)、肝动脉宽度(HA)及门静脉宽度(PV)变化。结果治疗30天时与对照组比较,TB il、DB il、R I显著降低[(51.60±4.53)μmol/L vs(53.65±4.16)μmol/L,(30.12±5.18)μmol/L vs(33.62±4.96)μmol/L,(0.70±0.04)vs(0.72±0.03),均P<0.05]。结论PGE1联合熊去氧胆酸治疗肝硬化残留黄疸是安全有效的,值得临床推广。
Objective To observe the efficacy and safety of prostaglandin E1 （PGE1） and ursofalk（UDCA） in remaining hyperbilirubinem of incipient hepatic cirrhosis. Methods Eighty-two patients with remaining hyperbilirubinem of incipient hepatic cirrhosis were randomly divided into two groups： the treated group, 46 cases and the control group, 36 cases. The control group took only regular Western medicine, the treated group took prostaglandin E1 and ursofalk as well as regular medicine. The course lasted for 30 days,the changes of total bilirubin （TBil）, direct billrubin（DBil）, indirect bilirubin（ IBil）, resistance index（RI）, hepatic artery （HA） and portal vein（PV） indices were examined before and after treatment. Results After 30 days, treatment,compared with the control group, TBil,DBil and RI were significantly decreased in the treated group（ P 〈0.05）, RI indices were improved after treatment in the treated group [（51.60±4.53）μmol/L vs（53.65±4.16）μmol/L,（30.12±5.18）μmol/L vs（33.62±4.96）μmol/L,（0.70±0.04）vs（0.72±0.03）, （ P 〈0.05）. Conclusion Prostaglandin E1 combined with ursofalk was safe and effective in treating remaining hyperbilirubinem of hepatic cirrhosis, suggesting its potentiality in clinical application.
出处
《临床荟萃》
CAS
北大核心
2006年第12期847-849,共3页
Clinical Focus
关键词
肝硬化
黄疸
前列腺素E1
熊去氧胆酸
hepatic cirrhosis
hyperbilirubinem
prostaglandin E1
ursofalk
